Anthropic Launches Claude Science: AI Workbench for Drug Discovery and Genomics

What Claude Science Actually Does

Anthropic describes Claude Science as an AI workbench for scientists. The platform consolidates tools for genomics, single-cell analysis, and proteomics into a single research environment—so researchers aren’t jumping between disconnected software to get work done.

The workbench can process inputs like 3D protein structures and genome browser tracks, and it works with an AI agent that helps researchers move from raw data to actionable insight. For large-scale analysis, the tool can draft a research plan that adapts to individual computing resources, which matters a lot when teams are working with different infrastructure setups.

Critically, Anthropic has built in an “assistant” function rather than an autonomous one. Researchers can critique and provide feedback to the software as they create and visualize data. That’s a deliberate design choice—keeping the scientist in the loop rather than replacing their judgment.

Where It Fits in the Research Workflow

Claude Science has already been applied to single-cell RNA sequencing analysis and CRISPR screen design, two areas where data processing demands are high and iteration cycles are long.

Michael Pollastri, a researcher at Northeastern University, put it plainly:

“If Claude Science is able to automate so much of the information gathering and help inform the ultimate decisions about where to go next, it would increase the pace of our experimentation by orders of magnitude.”

That’s not marketing language—that’s a working researcher describing a real bottleneck. Information gathering and decision support in early-stage drug discovery are notoriously time-consuming. Automating even a portion of that pipeline has measurable downstream effects on how fast teams can move.

The Broader Context

This launch comes shortly after the US lifted its export ban on Anthropic’s AI tools, prompting the company to re-release updated versions of several products, including Claude Fable 5 and Mythos 5. Claude Science appears to be part of a broader push by Anthropic to establish domain-specific AI tools rather than relying solely on general-purpose models.

Eric Kauderer-Abrams, Anthropic’s head of life sciences, framed the company’s intent directly:

“We’re doing this because we believe first and foremost that to build the right models, products and tools to accelerate the industry, we need to live it along with all of you.”

That signals something important. Anthropic isn’t positioning Claude Science as a product built from the outside looking in. They’re signaling active engagement with the life sciences community as part of the development process.

Why This Matters for Pharma and Biotech Teams

AI adoption in drug discovery and life sciences R&D has been accelerating for years. What’s changed is the quality and specificity of the tools now available. A general-purpose LLM can answer questions about genomics. A purpose-built workbench that processes protein structures, supports CRISPR screen design, and adapts to your computing environment is a different category of tool entirely.

For biotech teams evaluating AI tools right now, Claude Science is worth watching closely—especially if your workflows involve single-cell RNA analysis, proteomics, or early-stage drug target identification.

The real test will be how well it performs across diverse research environments and whether the feedback loop between researcher and AI agent holds up under real lab conditions. But the early academic reception suggests the direction is right.

The takeaway: Claude Science isn’t trying to replace researchers—it’s trying to remove the friction that slows them down. For pharma and biotech teams spending significant time on data gathering and analysis setup, that’s a concrete productivity lever worth evaluating.